The cut‐off of ALT, previously recommended by NASPGHAN for the screening of NAFLD and corresponding to 95th percentile of ALT in healthy weight, metabolically normal, liver disease‐free individuals, was reported in the Screening ALT For Elevation in Today's Youth (SAFETY) study.38 The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.